GBM

Companies GBM

News GBM

• analytica: Diverse range of information in related-events program

  Some 1,000 exhibitors from the laboratory-technology, analysis and biotechnology sectors will present their latest products at analytica in Munich from April 17 – 20. Besides the exhibition and the scientific analytica Conference, a practice-oriented program of related events awaits visitors. There more

• Preliminary registration report: analytica 2012 on the road to success

  It is still six months before the beginning of the fair, and analytica is already boasting some impressive, possibly record-breaking preliminary results: A total of 633 exhibitors have already registered for the fair (compared to 586 in 2009). As a result, the International Trade Fair for Laboratory more

• analytica 2012: Off to a successful start

  analytica 2012, the International Trade Fair for Analysis, Laboratory Technology and Biotechnology, does not begin for a year and nearly 80 percent of the space available in its five halls has already been booked by more than 500 exhibitors. Several leading German and international manufacturers hav more

Publications GBM

• Whole‐Genome mRNA Expression Profiling Identifies Functional and Prognostic Signatures in Patients with Mesenchymal Glioblastoma Multiforme

  Summary Background The Cancer Genome Atlas (TCGA) has divided patients with glioblastoma multiforme (GBM) into four subtypes based on mRNA expression microarray. The mesenchymal subtype, with a larger proportion, is considered a more lethal one. Clinical outcome prediction is required to bette more

• Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A [Research Papers]

  To identify key regulators of human brain tumor maintenance and initiation, we performed multiple genome-wide RNAi screens in patient-derived glioblastoma multiforme (GBM) stem cells (GSCs). These screens identified the plant homeodomain (PHD)-finger domain protein PHF5A as differentially required more

• Temozolomide modulated glioma proteome: Role of Interleukin‐1 receptor associated kinase‐4 (IRAK4) in chemosensitivity

  The current treatment for glioblastoma (GBM) includes temozolomide (TMZ) chemotherapy, yet the mechanism of action of TMZ is not thoroughly understood. Here, we investigated the TMZ induced changes in the proteome of the glioma derived cell line (U251) by 2D‐DIGE. We found 95 protein spots to be s more

Market studies GBM

• Glioblastoma Multiforme (GBM) – Pipeline Review, H2 2012

  Introduction Global Markets Direct’s, 'Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with latest updates, and spec more

• Glioblastoma Multiforme (GBM) – Pipeline Review, H1 2012

  Introduction Global Markets Direct’s, 'Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2012', provides an overview of the Glioblastoma Multiforme (GBM) therapeutic pipeline. This report provides information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with latest u more

• Bradmer Pharmaceuticals Inc. (BMR) - Financial and Strategic SWOT Analysis Review

  Bradmer Pharmaceuticals Inc. (Bradmer) is a publicly held life sciences company that is engaged in the development and marketing of drugs for the treatment of cancer. The company focuses on the treatment of Glioblastoma multiforme (GBM), an aggressive form of brain cancer. Its lead product include N more

Websites GBM